How integrins control breast biology

Current Opinion in Cell Biology

Volumn 25, Issue 5, 2013, Pages 633-641

  Glukhova, Marina A ^a,b   Streuli, Charles H ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRIN;

ADIPOCYTE; APICAL MEMBRANE; BREAST; BREAST CANCER; BREAST CELL; CANCER CELL; ENDOCYTOSIS; EXTRACELLULAR MATRIX; INTRADUCTAL CARCINOMA; MACROPHAGE; MAMMARY GLAND; METASTASIS; MORPHOGENESIS; MYOEPITHELIUM CELL; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; STEM CELL NICHE; TUMOR MICROENVIRONMENT;

ANIMALS; BREAST; BREAST NEOPLASMS; EXTRACELLULAR MATRIX; FEMALE; HUMANS; INTEGRINS; MAMMARY GLANDS, ANIMAL; NEOPLASTIC STEM CELLS; TUMOR MICROENVIRONMENT;

EID: 84882848445     PISSN: 09550674     EISSN: 18790410     Source Type: Journal    
DOI: 10.1016/j.ceb.2013.06.010     Document Type: Review

References (91)

1. Muschler J., Streuli C.H. Cell-matrix interactions in mammary gland development and breast cancer. Cold Spring Harb Perspect Biol 2010, 2:a003202.
2. Lu P., Weaver V.M., Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012, 196:395-406.
3. Raymond K., Faraldo M.M., Deugnier M.-A., Glukhova M.A. Integrins in mammary development. Semin Cell Dev Biol 2012, 23:599-605.
4. Streuli C.H. Integrins and cell-fate determination. J Cell Sci 2009, 122:171-177.
5. Katz E., Streuli C.H. The extracellular matrix as an adhesion checkpoint for mammary epithelial function. Int J Biochem Cell Biol 2007, 39:715-726.
6. Eyckmans J., Boudou T., Yu X., Chen C.S. A hitchhiker's guide to mechanobiology. Dev Cell 2011, 21:35-47.
7. Huck L., Pontier S.M., Zuo D.M., Muller W.J. beta1-integrin is dispensable for the induction of ErbB2 mammary tumors but plays a critical role in the metastatic phase of tumor progression. Proc Natl Acad Sci USA 2010, 107:15559-15564.
8. White D.E., Kurpios N.A., Zuo D., Hassell J.A., Blaess S., Mueller U., Muller W.J. Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 2004, 6:159-170.
9. Guo W., Pylayeva Y., Pepe A., Yoshioka T., Muller W.J., Inghirami G., Giancotti F.G. Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell 2006, 126:489-502.
10. Van Keymeulen A., Rocha A.S., Ousset M., Beck B., Bouvencourt G., Rock J., Sharma N., Dekoninck S., Blanpain C. Distinct stem cells contribute to mammary gland development and maintenance. Nature 2011, 479:189-193.
11. Li N., Zhang Y., Naylor M.J., Schatzmann F., Maurer F., Wintermantel T., Schuetz G., Mueller U., Streuli C.H., Hynes N.E. Beta1 integrins regulate mammary gland proliferation and maintain the integrity of mammary alveoli. EMBO J 2005, 24:1942-1953.
12. Taddei I., Deugnier M.-A., Faraldo M.M., Petit V., Bouvard D., Medina D., Fässler R., Thiery J.P., Glukhova M.A. Beta1 integrin deletion from the basal compartment of the mammary epithelium affects stem cells [Internet]. Nat Cell Biol 2008, 10:716-722.
13. Smalley M.J., Kendrick H., Sheridan J.M., Regan J.L., Prater M.D., Lindeman G.J., Watson C.J., Visvader J.E., Stingl J. Isolation of mouse mammary epithelial subpopulations: a comparison of leading methods. J Mammary Gland Biol Neoplasia 2012, 17:91-97.
14. Shehata M., Teschendorff A., Sharp G., Novcic N., Russell I.A., Avril S., Prater M., Eirew P., Caldas C., Watson C.J., et al. Phenotypic and functional characterisation of the luminal cell hierarchy of the mammary gland. Breast Cancer Res 2012, 14:R134.
15. Vaillant F., Asselin-Labat M.-L., Shackleton M., Forrest N.C., Lindeman G.J., Visvader J.E. The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res 2008, 68:7711-7717.
16. Lo P.-K., Kanojia D., Liu X., Singh U.P., Berger F.G., Wang Q., Chen H. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling. Oncogene 2012, 31:2614-2626.
17. Cariati M., Naderi A., Brown J.P., Smalley M.J., Pinder S.E., Caldas C., Purushotham A.D. Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Cancer 2008, 122:298-304.
18. Gilmore A.P., Metcalfe A.D., Romer L.H., Streuli C.H. Integrin-mediated survival signals regulate the apoptotic function of Bax through its conformation and subcellular localization. J Cell Biol 2000, 149:431-446.
19. Schellenberg B., Wang P., Keeble J.A., Rodriguez-Enriquez R., Walker S., Owens T.W., Foster F., Tanianis-Hughes J., Brennan K., Streuli C.H., et al. Bax exists in a dynamic equilibrium between the cytosol and mitochondria to control apoptotic priming. Mol Cell 2013, doi:10.1016/j.molcel.2012.12.022.
20. Cicalese A., Bonizzi G., Pasi C.E., Faretta M., Ronzoni S., Giulini B., Brisken C., Minucci S., Di Fiore P.P., Pelicci P.G. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 2009, 138:1083-1095.
21. Luo M., Fan H., Nagy T., Wei H., Wang C., Liu S., Wicha M.S., Guan J.-L. Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res 2009, 69:466-474.
22. Goel H.L., Pursell B., Standley C., Fogarty K., Mercurio A.M. Neuropilin-2 regulates α6β1 integrin in the formation of focal adhesions and signaling. J Cell Sci 2012, 125:497-506.
23. Goel H.L., Pursell B., Chang C., Shaw L.M., Mao J., Simin K., Kumar P., Kooi C.W.V., Shultz L.D., Greiner D.L., et al. GLI1 regulates a novel neuropilin-2/α6β1 integrin based autocrine pathway that contributes to breast cancer initiation. EMBO Mol Med 2013, 10.1002/emmm.201202078.
24. Hinck L., Silberstein G.B. Key stages in mammary gland development: the mammary end bud as a motile organ. Breast Cancer Res 2005, 7:245.
25. Klinowska T.C., Soriano J.V., Edwards G.M., Oliver J.M., Valentijn A.J., Montesano R., Streuli C.H. Laminin and beta1 integrins are crucial for normal mammary gland development in the mouse. Dev Biol 1999, 215:13-32.
26. Lu P., Ewald A.J., Martin G.R., Werb Z. Genetic mosaic analysis reveals FGF receptor 2 function in terminal end buds during mammary gland branching morphogenesis. Dev Biol 2008, 321:77-87.
27. Ewald A.J., Brenot A., Duong M., Chan B.S., Werb Z. Collective epithelial migration and cell rearrangements drive mammary branching morphogenesis. Dev Cell 2008, 14:570-581.
28. Brownfield D.G., Venugopalan G., Lo A., Mori H., Tanner K., Fletcher D.A., Bissell M.J. Patterned Collagen fibers orient branching mammary epithelium through distinct signaling modules. Current Biology 2013, 23:703-709.
29. Sakakura T., Nishizuka Y., Dawe C.J. Mesenchyme-dependent morphogenesis and epithelium-specific cytodifferentiation in mouse mammary gland. Science 1976, 194:1439-1441.
30. Onodera T., Sakai T., Hsu J.C., Matsumoto K., Chiorini J.A., Yamada K.M. Btbd7 regulates epithelial cell dynamics and branching morphogenesis. Science 2010, 329:562-565.
31. Daley W.P., Kohn J.M., Larsen M. A focal adhesion protein-based mechanochemical checkpoint regulates cleft progression during branching morphogenesis. Dev Dyn 2011, 240:2069-2083.
32. Rebustini I.T., Myers C., Lassiter K.S., Surmak A., Szabova L., Holmbeck K., Pedchenko V., Hudson B.G., Hoffman M.P. MT2-MMP-dependent release of collagen IV NC1 domains regulates submandibular gland branching morphogenesis. Dev Cell 2009, 17:482-493.
33. Mori H., Lo A.T., Inman J.L., Alcaraz J., Ghajar C.M., Mott J.D., Nelson C.M., Chen C.S., Zhang H., Bascom J.L., et al. Transmembrane/cytoplasmic, rather than catalytic, domains of Mmp14 signal to MAPK activation and mammary branching morphogenesis via binding to integrin β1. Development 2013, 140:343-352.
34. Nguyen-Ngoc K.-V., Cheung K.J., Brenot A., Shamir E.R., Gray R.S., Hines W.C., Yaswen P., Werb Z., Ewald A.J. ECM microenvironment regulates collective migration and local dissemination in normal and malignant mammary epithelium. Proc Natl Acad Sci USA 2012, 109:E2595-E2604.
35. Yoshida T., Matsumoto E., Hanamura N., Kalembeyi I., Katsuta K., Ishihara A., Sakakura T. Co-expression of tenascin and fibronectin in epithelial and stromal cells of benign lesions and ductal carcinomas in the human breast. J Pathol 1997, 182:421-428.
36. Raymond K., Cagnet S., Kreft M., Janssen H., Sonnenberg A., Glukhova M.A. Control of mammary myoepithelial cell contractile function by α3β1 integrin signalling. EMBO J 2011, 30:1896-1906.
37. Akhtar N., Streuli C.H. An integrin-ILK-microtubule network orients cell polarity and lumen formation in glandular epithelium. Nat Cell Biol 2013, 15:17-27.
38. Wickström S.A., Lange A., Hess M.W., Polleux J., Spatz J.P., Krüger M., Pfaller K., Lambacher A., Bloch W., Mann M., et al. Integrin-linked kinase controls microtubule dynamics required for plasma membrane targeting of caveolae. Dev Cell 2010, 19:574-588.
39. Hotta A., Kawakatsu T., Nakatani T., Sato T., Matsui C., Sukezane T., Akagi T., Hamaji T., Grigoriev I., Akhmanova A., et al. Laminin-based cell adhesion anchors microtubule plus ends to the epithelial cell basal cortex through LL5alpha/beta. J Cell Biol 2010, 189:901-917.
40. Ahmed S.M., Thériault B.L., Uppalapati M., Chiu C.W.N., Gallie B.L., Sidhu S.S., Angers S. KIF14 negatively regulates Rap1a-Radil signaling during breast cancer progression. J Cell Biol 2012, 199:951-967.
41. Naylor M.J., Li N., Cheung J., Lowe E.T., Lambert E., Marlow R., Wang P., Schatzmann F., Wintermantel T., Schuetz G., et al. Ablation of beta1 integrin in mammary epithelium reveals a key role for integrin in glandular morphogenesis and differentiation. J Cell Biol 2005, 171:717-728.
42. Akhtar N., Streuli C.H. Rac1 links integrin-mediated adhesion to the control of lactational differentiation in mammary epithelia. J Cell Biol 2006, 173:781-793.
43. Akhtar N., Marlow R., Lambert E., Schatzmann F., Lowe E.T., Cheung J., Katz E., Li W., Wu C., Dedhar S., et al. Molecular dissection of integrin signalling proteins in the control of mammary epithelial development and differentiation. Development 2009, 136:1019-1027.
44. Edwards G.M., Wilford F.H., Liu X., Hennighausen L., Djiane J., Streuli C.H. Regulation of mammary differentiation by extracellular matrix involves protein-tyrosine phosphatases. J Biol Chem 1998, 273:9495-9500.
45. Zoubiane G.S., Valentijn A., Lowe E.T., Akhtar N., Bagley S., Gilmore A.P., Streuli C.H. A role for the cytoskeleton in prolactin-dependent mammary epithelial cell differentiation. J Cell Sci 2004, 117:271-280.
46. Du J.-Y., Chen M.-C., Hsu T.-C., Wang J.-H., Brackenbury L., Lin T.-H., Wu Y.-Y., Yang Z., Streuli C.H., Lee Y.-J. The RhoA-Rok-myosin II pathway is involved in extracellular matrix-mediated regulation of prolactin signaling in mammary epithelial cells. J Cell Physiol 2012, 227:1553-1560.
47. Mammoto A., Mammoto T., Ingber D.E. Mechanosensitive mechanisms in transcriptional regulation. J Cell Sci 2012, 10.1242/jcs.093005.
48. Streuli C.H., Akhtar N. Signal co-operation between integrins and other receptor systems. Biochem J 2009, 418:491-506.
49. Jeanes A.I., Wang P., Moreno-Layseca P., Paul N., Cheung J., Tsang R., Akhtar N., Foster F.M., Brennan K., Streuli C.H. Specific β-containing integrins exert differential control on proliferation and two-dimensional collective cell migration in mammary epithelial cells. J Biol Chem 2012, 287:24103-24112.
50. Wang P., Ballestrem C., Streuli C.H. The C terminus of talin links integrins to cell cycle progression. J Cell Biol 2011, 195:499-513.
51. Dos Santos P.B., Zanetti J.S., Ribeiro-Silva A., Beltrao E.I. Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study. Diagn Pathol 2012, 7:104.
52. Yao E.S., Zhang H., Chen Y.-Y., Lee B., Chew K., Moore D., Park C. Increased beta1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res 2007, 67:659-664.
53. Bianchi-Smiraglia A., Paesante S., Bakin A.V. Integrin β5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways. Oncogene 2012, doi:10.1038/onc.2012.320.
54. Goodman S.L., Grote H.J., Wilm C. Matched rabbit monoclonal antibodies against αv-series integrins reveal a novel αvβ3-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors. Biol Open 2012, 1:329-340.
55. Lane J., Martin T.A., Mansel R.E., Jiang W.G. The expression and prognostic value of the guanine nucleotide exchange factors (GEFs) Trio, Vav1 and TIAM-1 in human breast cancer. Int Seminars Surg Oncol 2008, 5.
56. Lee K., Liu Y., Mo J.Q., Zhang J., Dong Z., Lu S. Vav3 oncogene activates estrogen receptor and its overexpression may be involved in human breast cancer. BMC Cancer 2008, 8:158.
57. Sosa M.S., Lopez-Haber C., Yang C., Wang H., Lemmon M.A., Busillo J.M., Luo J., Benovic J.L., Klein-Szanto A., Yagi H., et al. Identification of the Rac-GEF P-Rex1 as an essential mediator of ErbB signaling in breast cancer. Mol Cell 2010, 40:877-892.
58. Zouq N.K., Keeble J.A., Lindsay J., Valentijn A.J., Zhang L., Mills D., Turner C.E., Streuli C.H., Gilmore A.P. FAK engages multiple pathways to maintain survival of fibroblasts and epithelia: differential roles for paxillin and p130Cas. J Cell Sci 2009, 122:357-367.
59. Sin S., Bonin F., Petit V., Meseure D., Lallemand F., Bièche I., Bellahcène A., Castronovo V., De Wever O., Gespach C., et al. Role of the focal adhesion protein kindlin-1 in breast cancer growth and lung metastasis. J Natl Cancer Inst 2011, 103:1323-1337.
60. Klinowska T.C., Alexander C.M., Georges-Labouesse E., Van der Neut R., Kreidberg J.A., Jones C.J., Sonnenberg A., Streuli C.H. Epithelial development and differentiation in the mammary gland is not dependent on alpha 3 or alpha 6 integrin subunits. Dev Biol 2001, 233:449-467.
61. Lu S., Simin K., Khan A., Mercurio A.M. Analysis of integrin beta4 expression in human breast cancer: association with basal-like tumors and prognostic significance. Clin Cancer Res 2008, 14:1050-1058.
62. Leung C.T., Brugge J.S. Outgrowth of single oncogene-expressing cells from suppressive epithelial environments. Nature 2012, 482:410-413.
63. Emery L.A., Tripathi A., King C., Kavanah M., Mendez J., Stone M.D., De las Morenas A., Sebastiani P., Rosenberg C.L. Early dysregulation of cell adhesion and extracellular matrix pathways in breast cancer progression. Am J Pathol 2009, 175:1292-1302.
64. McCaffrey L.M., Montalbano J., Mihai C., Macara I.G. Loss of the Par3 polarity protein promotes breast tumorigenesis and metastasis. Cancer Cell 2012, 22:601-614.
65. Xue B., Krishnamurthy K., Allred D.C., Muthuswamy S.K. Loss of Par3 promotes breast cancer metastasis by compromising cell-cell cohesion. Nat Cell Biol 2012, 15:189-200.
66. 1 integrin is a metastasis suppressor in mouse models and human cancer. J Clin Invest 2011, 121:226-237.
67. Baranwal S., Wang Y., Rathinam R., Lee J., Jin L., McGoey R., Pylayeva Y., Giancotti F., Blobe G.C., Alahari S.K. Molecular characterization of the tumor-suppressive function of nischarin in breast cancer. J Natl Cancer Inst 2011, 103:1513-1528.
68. Citterio C., Menacho-Márquez M., García-Escudero R., Larive R.M., Barreiro O., Sánchez-Madrid F., Paramio J.M., Bustelo X.R. The rho exchange factors vav2 and vav3 control a lung metastasis-specific transcriptional program in breast cancer cells. Sci Signal 2012, 5:ra71.
69. Robinson S.D., Hodivala-Dilke K.M. The role of β3-integrins in tumor angiogenesis: context is everything. Curr Opin Cell Biol 2011, 23:630-637.
70. Taverna D., Crowley D., Connolly M., Bronson R.T., Hynes R.O. A direct test of potential roles for beta3 and beta5 integrins in growth and metastasis of murine mammary carcinomas. Cancer Res 2005, 65:10324-10329.
71. Yang X., Pursell B., Lu S., Chang T.-K., Mercurio A.M. Regulation of beta 4-integrin expression by epigenetic modifications in the mammary gland and during the epithelial-to-mesenchymal transition. J Cell Sci 2009, 122:2473-2480.
72. Mostovich L.A., Prudnikova T.Y., Kondratov A.G., Loginova D., Vavilov P.V., Rykova V.I., Sidorov S.V., Pavlova T.V., Kashuba V.I., Zabarovsky E.R., et al. Integrin alpha9 (ITGA9) expression and epigenetic silencing in human breast tumors. Cell Adh Migr 2011, 5:395-401.
73. Mulder K.W., Wang X., Escriu C., Ito Y., Schwarz R.F., Gillis J., Sirokmány G., Donati G., Uribe-Lewis S., Pavlidis P., et al. Diverse epigenetic strategies interact to control epidermal differentiation. Nat Cell Biol 2012, 14:753-763.
74. Shah S.P., Roth A., Goya R., Oloumi A., Ha G., Zhao Y., Turashvili G., Ding J., Tse K., Haffari G., et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012, 486:395-399.
75. DuFort C.C., Paszek M.J., Weaver V.M. Balancing forces: architectural control of mechanotransduction. Nat Rev Mol Cell Biol 2011, 12:308-319.
76. Conklin M.W., Eickhoff J.C., Riching K.M., Pehlke C.A., Eliceiri K.W., Provenzano P.P., Friedl A., Keely P.J. Aligned collagen is a prognostic signature for survival in human breast carcinoma. Am J Pathol 2011, 178:1221-1232.
77. Lim S.-T., Chen X.L., Lim Y., Hanson D.A., Vo T.-T., Howerton K., Larocque N., Fisher S.J., Schlaepfer D.D., Ilic D: Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. Mol Cell 2008, 29:9-22.
78. Provenzano P.P., Keely P.J. Mechanical signaling through the cytoskeleton regulates cell proliferation by coordinated focal adhesion and Rho GTPase signaling. J Cell Sci 2011, 124:1195-1205.
79. Gerson K.D., Shearstone J.R., Maddula V.S.R.K., Seligmann B.E., Mercurio A.M. Integrin β4 regulates SPARC protein to promote invasion. J Biol Chem 2012, 287:9835-9844.
80. Nagaharu K., Zhang X., Yoshida T., Katoh D., Hanamura N., Kozuka Y., Ogawa T., Shiraishi T., Imanaka-Yoshida K. Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells. Am J Pathol 2011, 178:754-763.
81. Oskarsson T., Acharyya S., Zhang X.H.-F., Vanharanta S., Tavazoie S.F., Morris P.G., Downey R.J., Manova-Todorova K., Brogi E., Massagué J. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med 2011, 17:867-874.
82. Kharaishvili G., Cizkova M., Bouchalova K., Mgebrishvili G., Kolar Z., Bouchal J. Collagen triple helix repeat containing 1 protein, periostin and versican in primary and metastatic breast cancer: an immunohistochemical study. J Clin Pathol 2011, 64:977-982.
83. Malanchi I., Santamaria-Martínez A., Susanto E., Peng H., Lehr H.-A., Delaloye J.-F., Huelsken J. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012, 481:85-89.
84. Barkan D., Chambers A.F. β1-integrin: a potential therapeutic target in the battle against cancer recurrence. Clin Cancer Res 2011, 17:7219-7223.
85. Nam J.-M., Onodera Y., Bissell M.J., Park C.C. Breast cancer cells in three-dimensional culture display an enhanced radioresponse after coordinate targeting of integrin alpha5beta1 and fibronectin. Cancer Res 2010, 70:5238-5248.
86. Park C.C., Zhang H.J., Yao E.S., Park C.J., Bissell M.J. Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts [Internet]. Cancer Res 2008, 68:4398-4405.
87. Goodman S.L., Picard M. Integrins as therapeutic targets. Trends Pharmacol Sci 2012, 33:405-412.
88. Bretschi M., Merz M., Komljenovic D., Berger M.R., Semmler W., Bäuerle T. Cilengitide inhibits metastatic bone colonization in a nude rat model. Oncol Rep 2011, 26:843-851.
89. Bäuerle T., Komljenovic D., Merz M., Berger M.R., Goodman S.L., Semmler W. Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study. Int J Cancer 2011, 128:2453-2462.
90. Schmid M.C., Avraamides C.J., Foubert P., Shaked Y., Kang S.W., Kerbel R.S., Varner J.A. Combined blockade of integrin-α4β1 plus cytokines SDF-1α or IL-1β potently inhibits tumor inflammation and growth. Cancer Res 2011, 71:6965-6975.
91. Wu J., Jiang Y., Yang W., He Z., Meng S., Zhang Q., Lin M., Zhang H., Li W., Yang Y., et al. Dual function of RGD-modified VEGI-192 for breast cancer treatment. Bioconjug Chem 2012, 23:796-804.